Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.71

+0.93%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$343.75M
EPS-0.4700
P/E Ratio-5.76
Earnings Date08/04/2026

naut

Sales/Maturities of Investments

Last Annual Value

108.99M

3-Year CAGR

-13%

5-Year CAGR

20%

10-Year CAGR

%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Sales/Maturities of Investments

NAUT · NASDAQ
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
108.99M
15.0%5.1%N/A 
56.70M
-19.0%N/AN/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
0.00
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
0.00
N/AN/AN/A
0.00
N/AN/AN/A
111.42M
51.3%N/AN/A
0.00
N/AN/AN/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
579.00K
-73.2%N/A-39.3%
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.705, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.705